Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
Nicolas R Barthélemy, Gemma Salvadó, Suzanne E. Schindler, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1085-1095
Open Access | Times Cited: 162

Showing 26-50 of 162 citing articles:

Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer’s Disease in Blood
Jianman Wang, Xing Lü, Yao He
Biosensors (2025) Vol. 15, Iss. 2, pp. 85-85
Open Access | Times Cited: 1
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study
Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 1
Development of Neurodegenerative Disease Diagnosis and Monitoring from Traditional to Digital Biomarkers
Jaeyoon Song, E. Cho, H. -J. Lee, et al.
Biosensors (2025) Vol. 15, Iss. 2, pp. 102-102
Open Access | Times Cited: 1
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
Linda Karlsson, Jacob W. Vogel, Ida Arvidsson, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
Cut‐points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice
Jemma Hazan, Kathy Liu, Jeremy D. Isaacs, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access | Times Cited: 1
Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies
Xingyu Zhang, Jiangyu Wang, Zhentao Zhang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care
Alireza Atri, Bradford C. Dickerson, Carolyn Clevenger, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 8
Benchmarking of a multi-biomarker low-volume panel for Alzheimer’s Disease and related dementia research
Laura Ibáñez, Menghan Liu, Aleksandra Beric, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 7
In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives
Simone Baiardi, Oskar Hansson, Johannes Levin, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5757-5770
Open Access | Times Cited: 7
Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care?
Lawren VandeVrede, Gil D. Rabinovici
JAMA Neurology (2024) Vol. 81, Iss. 10, pp. 1030-1030
Closed Access | Times Cited: 7
Effect of long-term physical exercise and multidomain interventions on cognitive function and the risk of mild cognitive impairment and dementia in older adults: a systematic review with meta-analysis
Imanol Reparaz‐Escudero, Míkel Izquierdo, Heike A. Bischoff‐Ferrari, et al.
Ageing Research Reviews (2024) Vol. 100, pp. 102463-102463
Closed Access | Times Cited: 7
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Noëlle Warmenhoven, Gemma Salvadó, Shorena Janelidze, et al.
Brain (2024)
Open Access | Times Cited: 7
Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Sandar Aye, Ron Handels, Bengt Winblad, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 6
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer’s Disease. Are We Ready for the New Era?
Roxanna Korologou‐Linden, J. Kalsi, Dimitra Kafetsouli, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 6
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Viswanath Devanarayan, T. Doherty, Arnaud Charil, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5617-5628
Open Access | Times Cited: 6
The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study
Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Rumiana Tenchov, Janet M. Sasso, Qiongqiong Angela Zhou
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 21, pp. 3800-3827
Open Access | Times Cited: 6
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Michael T. Heneka, David Morgan, Frank Jessen
The Lancet (2024) Vol. 404, Iss. 10468, pp. 2198-2208
Closed Access | Times Cited: 6
Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research
Laura Ibáñez, Menghan Liu, Aleksandra Beric, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 6
Influence of medical conditions on the diagnostic accuracy of plasma p‐tau217 and p‐tau217/Aβ42
Marcos Olvera‐Rojas, Kelsey R. Sewell, Thomas K. Karikari, et al.
Alzheimer s & Dementia (2024)
Closed Access | Times Cited: 6
Evaluating p-tau217 and p-tau231 as Biomarkers for Early Diagnosis and Differentiation of Alzheimer’s Disease: A Narrative Review
Dorian Julian Jarek, Hubert Mizerka, Jarosław Nuszkiewicz, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 786-786
Open Access | Times Cited: 5
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
Michael Rosenbloom, Tricia O’Donohue, Domi Zhou-Clark, et al.
CNS Drugs (2024) Vol. 38, Iss. 7, pp. 493-505
Open Access | Times Cited: 5
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies
Reisa A. Sperling, Michael Donohue, Robert A. Rissman, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 5
Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
Amit Etkin, Jessica Powell, Adam Savitz
Neuropsychopharmacology (2024) Vol. 50, Iss. 1, pp. 258-268
Open Access | Times Cited: 5
Diaper-based wearable SERS sensing system with a silver nano dual-structure composite hydrogel for the detection of biomarkers and pH in urine
Ru Liu, Qingling Nie, Yanhanzhuo Wang, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 155207-155207
Closed Access | Times Cited: 5

Scroll to top